BioXcel Therapeutics
Yahoo Finance • 9 days ago
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements
NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it ha... Full story
Yahoo Finance • 17 days ago
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p<.05) Complete resolution of agitation was significantly higher with BXCL501 compared to placeb... Full story
Yahoo Finance • 30 days ago
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT STSSW [https://www.chartmill.com/stock/quote/STSSW/profile] 86.83%... Full story
Yahoo Finance • last month
Which stocks are experiencing notable movement on Wednesday?
Intrigued by the market activity in the middle of the day on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT STSSW [https://ww... Full story
Yahoo Finance • last month
The market is filled with gapping stocks in Wednesday's session.
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT NBY [https://www.chartmill.com/sto... Full story
Yahoo Finance • last month
UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®
BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While... Full story
Yahoo Finance • last month
Get insights into the top gainers and losers of Tuesday's after-hours session.
After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE... Full story
Yahoo Finance • last month
BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025
NEW HAVEN, Conn., Aug. 26, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it wil... Full story
Yahoo Finance • last month
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Data from more than 2,600 agitation episodes collected Topline data readout is on track for August NEW HAVEN, Conn., Aug. 19, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing art... Full story
Yahoo Finance • last month
These stocks are moving in today's pre-market session
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT V... Full story
Yahoo Finance • last month
Stocks Moving Premarket: PPCB, BTAI, TNXP, DAY, TPIC, And Other Gainers & Losers
(RTTNews) - At 6.50 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell. For active traders, premarket trading offers a he... Full story
Yahoo Finance • last month
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
Achieved alignment with the FDA on sNDA package to expand the IGALMI label for the At-Home (Outpatient) setting sNDA submission on track for Q1 2026 NEW HAVEN, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq... Full story
Yahoo Finance • last month
Wondering what's happening in today's after-hours session?
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT DHAI [https://www.chartmill.com/stock/quote/DHAI/profile... Full story
Yahoo Finance • last month
BioXcel Therapeutics receives FDA feedback ahead of planned pre-sNDA meeting
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced Thursday that it has received preliminary comments from the U.S. Food and Drug Administration (FDA) in advance of a pre-supplemental New Drug Application (pre-sNDA) meeting scheduled for A... Full story
Yahoo Finance • last month
3 Supercharged Stocks Flashing Strong Momentum Signals
Several stocks have shown strong momentum in recent sessions as broader markets charge to all-time highs. Here’s a look at some standout momentum movers that are just starting to pick up steam. 3 Momentum Names To Watch Benzinga’s rankin... Full story
Yahoo Finance • last month
BioXcel at Canaccord Genuity: Strategic Insights on Phase 3 Trials
On Tuesday, 12 August 2025, BioXcel Therapeutics (NASDAQ:BTAI) participated in Canaccord Genuity’s 45th Annual Growth Conference, offering a strategic overview of its upcoming Phase 3 trial data for BXCL501. The company emphasized both its... Full story
- T
Mentioned:
Yahoo Finance • 2 months ago
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates
Topline data from SERENITY At-Home Phase 3 trial for acute treatment of agitation associated with bipolar disorders or schizophrenia expected in August FDA meeting scheduled in August and is intended to support potential sNDA submission f... Full story
Yahoo Finance • 2 months ago
These stocks are moving in today's after hours session
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] AFTER HOURS GAINERS TICKER CHANGE COMMENT ANY [https://www.chartmill.com/stock/qu... Full story
Yahoo Finance • 2 months ago
Which stocks are experiencing notable movement on Monday?
Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] GAINERS TICKER CHANGE COMMENT EQ [https://www.chartmill.com/stock/quote/EQ/profile] 77.82% Positive ma... Full story
